Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | FABP4 | P15090 | 8/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MPL | P40238 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13719098 | 0.98 | ALDH1A1 (0.54) | ALDH1A1FABP4NPC1MAPK1MPL | |
| SCHEMBL3781603 | 0.98 | ALDH1A1 (0.54) | ALDH1A1FABP4NPC1MAPK1MPL | |
| SCHEMBL1415943 | 0.98 | ALDH1A1 (0.54) | ALDH1A1FABP4NPC1MAPK1MPL | |
| SCHEMBL5239888 | 0.89 | TTR (0.55) | ALDH1A1FABP4NPC1MAPK1MPL | |
| SCHEMBL9468792 | 0.85 | ALDH1A1 (0.46) | ALDH1A1FABP4NPC1MPLHTT | |
| SCHEMBL30855487 | 0.83 | ALDH1A1 (0.56) | ALDH1A1FABP4NPC1MAPK1SLC2A1 | |
| SCHEMBL15461561 | 0.83 | ALDH1A1 (0.56) | ALDH1A1FABP4NPC1MAPK1SLC2A1 | |
| SCHEMBL29409575 | 0.82 | TTR (0.61) | ALDH1A1MPLTSHRSMN1; SMN2 | |
| SCHEMBL703189 | 0.82 | TTR (0.61) | ALDH1A1MPLTSHRSMN1; SMN2 | |
| SCHEMBL639511 | 0.81 | ALDH1A1 (0.55) | ALDH1A1FABP4NPC1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | claimed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | claimed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | claimed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | claimed |
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3898588-B1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-3898588-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127960-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-9666436-B2 | Ion implantation methods | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9666436-B2 | Ion implantation methods | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2003087226-A1 | FILLER REINFORCED POLYETHER IMIDE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | GENERAL ELECTRIC COMPAMY (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030158309-A1 | Flame retardant aromatic polycarbonate resin composition and molded articles thereof | TEIJIN CHEMICALS LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| US-5081001-A | Blocked monomer and polymers therefrom for use as photoresists | HOECHST CELANESE CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0453126-A2 | Negative photoresist developable in aqueous base | HOECHST CELANESE CORPORATION (US) | 1991-10-23 | — | — | EP | disclosed |
| US-4962171-A | Blocked monomer and polymers therefrom for use as photoresists | HOECHST CELANESE CORPORATION (US) | 1990-10-09 | — | — | US | disclosed |
| US-4810613-A | Blocked monomer and polymers therefrom for use as photoresists | HOECHST CELANESE CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052586-A1 | DISUBSTITUTED ALKYNE DERIVATIVES | BRCA1, MYC, PCNA | ALDH1A1 414/4885FABP4 2123/4885NPC1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.